Last edited by Vudogrel
Sunday, May 10, 2020 | History

5 edition of Multiple drug resistance in cancer 2 found in the catalog.

Multiple drug resistance in cancer 2

molecular, cellular and clinical aspects

  • 360 Want to read
  • 35 Currently reading

Published by Kluwer Academic Publishers in Dordrecht, Boston .
Written in English

    Subjects:
  • Drug resistance in cancer cells,
  • Cancer -- Chemotherapy,
  • Drug Resistance, Neoplasm -- physiology,
  • Drug Resistance, Multiple,
  • Neoplasms -- drug therapy

  • Edition Notes

    Other titlesMultiple drug resistancce in cancer two, Cytotechnology.
    Statementedited by Martin Clynes.
    ContributionsClynes, M.
    Classifications
    LC ClassificationsRC271.C5 M845 1998
    The Physical Object
    Paginationxi, 344 p. :
    Number of Pages344
    ID Numbers
    Open LibraryOL387379M
    ISBN 100792352726
    LC Control Number98050221

      ABCB1 encodes Multidrug Resistance Protein which promotes efflux of chemotherapeutic and targeted agents. Here, in breast and ovarian cancer the authors identify multiple transcriptional fusion Cited by: 8. The principle mechanism of protection of stem cells is through the expression of ATP-binding cassette (ABC) transporters. These transporters serve as the guardians of the stem cell population in the body. Unfortunately these very same ABC efflux pumps afford protection to cancer stem cells in tumors, shielding them from the adverse effects of by:

      Multidrug resistance (MDR) is the mechanism by which many cancers develop resistance to chemotherapy drugs, resulting in minimal cell death and the expansion of drug-resistant tumors. Cancers have the ability to develop resistance to traditional therapies, and the increasing prevalence of these drug resistant cancers necessitates further research and treatment development. This paper outlines the current knowledge of mechanisms that promote or enable drug resistance, such as drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition Cited by:

      Overcoming cancer treatment resistance Apr. 20, — Drug resistance is a major obstacle in cancer treatment -- leading to relapse for many . The development of drug resistance to multiple cancer chemotherapeutic drugs is most likely caused by: An enzyme that can be modified by cancer cells, allowing them to continuously divide without limits and avoid entering this form of growth arrest is: A 51 year old woman with multiple risk factors is placed on the Selective Estrogen.


Share this book
You might also like
Land

Land

Communications media, globalization and empire

Communications media, globalization and empire

Reviews of physiology, biochemistry, and pharmacology.

Reviews of physiology, biochemistry, and pharmacology.

Korea, a mysterious country in the East

Korea, a mysterious country in the East

GRID, Global Resource Information Database, United Nations Environment Programme.

GRID, Global Resource Information Database, United Nations Environment Programme.

Safeguarding the public

Safeguarding the public

EU-company law

EU-company law

collection of poems called Conscious story

collection of poems called Conscious story

Seven precious gems.

Seven precious gems.

Report on the housing census held in four towns, May-August, 1960

Report on the housing census held in four towns, May-August, 1960

Liberalism in Ghana since independence

Liberalism in Ghana since independence

Multiple drug resistance in cancer 2 Download PDF EPUB FB2

Resistance to chemotherapy, and especially multi-drug resistance, represents a significant barrier to the successful treatment of cancer. This multi-author volume brings together a wide range of up-to-date reviews on different aspects of our knowledge of drug-resistance mechanisms, written.

Gopalakrishna Pillai, in Applications of Targeted Nano Drugs and Delivery Systems, 5 Multiple Drug Resistance. Multiple drug resistance (MDR) is a major factor in the failure of many chemotherapeutic agents and is a major challenge in cancer chemotherapy. Many cancers develop resistance, resulting in minimal cancer cell death and production of drug-resistant tumors.

Multiple drug resistance (MDR), multidrug resistance or multiresistance is antimicrobial resistance shown by a species of microorganism to at least one antimicrobial drug in three or more antimicrobial categories.

Antimicrobial categories are classifications of antimicrobial agents based on their mode of action and specific to target MDR types most threatening to public health. Antineoplastic resistance, often used interchangeably with chemotherapy resistance, is the resistance of neoplastic (cancerous) cells, or the ability of cancer cells to survive and grow despite anti-cancer therapies.

In some cases, cancers can evolve resistance to multiple drugs, called multiple drug resistance. There are two general causes of antineoplastic therapy failure: Inherent genetic. Primary Resistance. It occurs when the organism has never encountered the drug of interest in a particular host. Secondary Resistance.

Also known as “acquired resistance,” this term is used to describe the resistance that only arises in an organism after an exposure to the drug [5, 34].It may further be classified as by:   Multiple drug resistance (multidrug resistance; MDR), a phenomenon whereby human tumours that acquire resistance to one type of therapy are found to be resistant to several other drugs that are often quite different in both structure and mode of action, has been recognised clinically for several decades.

An important advance in our understanding of MDR came with the identification of P Cited by: Multi-drug resistance is very common in late-stage cancer patients who have gone through several rounds of chemotherapy in attempts to rid themselves of cancerous tumors, however the multi-drug resistance is rarely ever accounted for in traditional treatment.

The activation of the Pgp pumps is in direct relation to the dosing of chemotherapy. Clinically, drug resistance may develop either prior to drug therapy, or due to drug therapy. Cancer cells express multiple drug resistance (MDR) by initially developing resistance to a single anticancer drug, and slowly to various anticancer agents that are structurally similar but possess different mechanisms of.

Michael Gottesman, M.D., head of the multidrug resistance section of NCI's Center for Cancer Research, and his colleagues study how ABC transporters contribute to cancer drug than 30 years ago, they discovered that "in some cases, when patients go from being sensitive to resistant to treatment, their cancer cells start to overexpress ABC transporters," he said.

Mol Biotechnol. Nov;46(3) doi: /s Multiple drug resistance mechanisms in cancer. Baguley BC(1). Author information: (1)Auckland Cancer Society Research Centre, The University of Auckland, Private BagAuckland,New Zealand.

[email protected] Multiple drug resistance (multidrug resistance; MDR), a phenomenon Cited by: multiple drug resistance: [ re-zis´tans ] 1. opposition, or counteracting force, as opposition of a conductor to passage of electricity or other energy or substance.

the natural ability of a normal organism to remain unaffected by noxious agents in its environment; see also immunity. in psychology or psychiatry, conscious or unconscious. Drug Efflux. One of the most studied mechanisms of cancer drug resistance involves reducing drug accumulation by enhancing efflux.

Members of the ATP-binding cassette (ABC) transporter family proteins enable this efflux and are important, well Cited by: In the present study, ATP binding cassette (ABC) efflux transporters including breast cancer resistance protein (BCRP), P-glycoprotein (P-gp-MDR1), multidrug resistance protein (MRP) 2, MRP3 and.

Effective control of multiple-drug resistant enterococci will require 1) better understanding of the interaction between enterococci, the hospital environment, and humans, 2) prudent antibiotic use, 3) better contact isolation in hospitals and other patient care environments, and 4) improved surveillance.

This book reviews the mechanisms and clinical implications of drug resistance in cancer with unrivalled authority.

Chapters cover topics of current clinical concern, including multiple drug resistance and its reversal, topoisomerase drugs, apoptosis, dose intensity and escalation, gene therapy and haematopoietic by: One type of cancer with multiple mechanisms of drug resistance is Diffuse Large B Cell Lymphoma (DLBCL).

Many clinical trials testing a single drug to treat DLBCL have been unsuccessful due to the development of drug resistance. To overcome these challenges, NCI researchers, in collaboration with cancer centers, are testing combinations of. Multidrug resistance in cancer Article (PDF Available) in BMJ Clinical Research () February with 77 Reads How we measure 'reads'.

Multiple-Drug Resistance in Human Cancer. Ira Pastan, M.D., and Michael Gottesman, M.D. This article has no abstract; the first words appear by: The drug resistance in cancer cells often results from elevated expression of particular proteins, such as cell‐membrane transporters, which can result in an increased efflux of the cytotoxic drugs from the cancer cells, thus lowering their intracellular concentrations [4, 6, 9].Cited by:   Multiple drug resistance or Multidrug resistance is a condition enabling a disease-causing organism to resist distinct drugs or chemicals of a wide variety of structure and function targeted at eradicating the organism.

Organisms that display multidrug resistance can be pathologic cells, including bacterial and neoplastic cells. Multidrug. If the molecular basis of drug resistance could be understood, new types of treatment might be developed to cure these drug-resistant resistance has been studied in cancer cells grown Cited by: Development of [11]C-Colchicine for the Noninvasive Diagnosis and Quantitation of Multi-drug Resistance by Positron Emission Tomography.

Tumor multiple drug resistance (MDR) is defined as the property of cancer cells to resist the action of a large variety of chemically and functionally unrelated substances, including but not limited to chemotherapeutic drugs./DONNENBERG AND DONNENBERGMULTIPLE DRUG RESISTANCE IN CANCER REVISITEDINVITED REVIEW AND COMMENTARY Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis Vera S.

Donnenberg, PhD, and Albert D. Donnenberg, PhD The failure to eradicate most cancers may be as fun-damental as a misidentification of the Cited by: